| 4.64 0.21 (4.74%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.46 |
1-year : | 6.38 |
| Resists | First : | 4.67 |
Second : | 5.46 |
| Pivot price | 3.63 |
|||
| Supports | First : | 3.04 |
Second : | 2.03 |
| MAs | MA(5) : | 4.21 |
MA(20) : | 3.4 |
| MA(100) : | 2.4 |
MA(250) : | 5.02  |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 94 |
D(3) : | 89.1 |
| RSI | RSI(14): 72.9 |
|||
| 52-week | High : | 33.97 | Low : | 1.14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SAVA ] has closed below upper band by 1.5%. Bollinger Bands are 197.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.69 - 4.7 | 4.7 - 4.72 |
| Low: | 4.3 - 4.33 | 4.33 - 4.35 |
| Close: | 4.61 - 4.64 | 4.64 - 4.67 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Mon, 06 Oct 2025
Cassava Sciences (SAVA): Lucid Capital Markets Initiates Coverage with Buy Rating | SAVA Stock News - GuruFocus
Mon, 06 Oct 2025
LUCID CAPITAL MARKETS Initiates Coverage of Cassava Sciences (SAVA) with Buy Recommendation - Nasdaq
Sat, 27 Sep 2025
What Does Cassava Sciences (SAVA) CEO’s Insider Buy Reveal About Its Post-Alzheimer’s Strategy? - Sahm
Sat, 27 Sep 2025
Cassava Sciences (SAVA): Evaluating Valuation After CEO’s Major Share Purchase and Alzheimer’s Program Withdrawal - Yahoo Finance
Thu, 25 Sep 2025
Cassava Sciences: Fundamentals Update After Big Move On Insider Purchases (NASDAQ:SAVA) - Seeking Alpha
Tue, 23 Sep 2025
Cassava Sciences (SAVA) Insider Trade Alert! CEO Richard Barry Buys Stock - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 12.7 (%) |
| Held by Institutions | 25.1 (%) |
| Shares Short | 7,430 (K) |
| Shares Short P.Month | 6,130 (K) |
| EPS | -2.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.7 % |
| Return on Equity (ttm) | -89 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.18 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -96 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -1.77 |
| PEG Ratio | 0 |
| Price to Book value | 2.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.34 |
| Dividend | 5.25 |
| Forward Dividend | 0 |
| Dividend Yield | 113.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|